Shionogi & Co Ltd 2024 IR
The report highlights Shionogi & Co., Ltd.'s performance and strategic progress for fiscal 2023, achieving record-high revenue and operating profit. The company advanced its transformation into a Healthcare as a Service (HaaS) company, focusing on infectious diseases and quality of life (QOL) diseases. Key achievements include obtaining domestic approval for the COVID-19 vaccine Covgoze and expanding global sales of the antibiotic Fetroja. Shionogi also strengthened its pipeline through the acquisition of Qpex Biopharma and a joint venture with Apnimed.
Company: Shionogi & Co Ltd
Sector: Health Care
Country: Japan
Year: 2024
Type: IR
Pages: 66
Shionogi & Co Ltd
Integrated Report
The report highlights Shionogi & Co., Ltd.'s performance and strategic progress for fiscal 2023, achieving record-high revenue and operating profit. The company advanced its transformation into a Healthcare as a Service (HaaS) company, focusing on infectious diseases and quality of life (QOL) diseases. Key achievements include obtaining domestic approval for the COVID-19 vaccine Covgoze and expanding global sales of the antibiotic Fetroja. Shionogi also strengthened its pipeline through the acquisition of Qpex Biopharma and a joint venture with Apnimed.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Published
Nov 8, 2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees